Randomized, Placebo Controlled Blinded Study to Assess the Efficacy of Valsartan to Prevent Left Ventricle Remodeling in Patients With Dual Chamber Pacemaker
Phase of Trial: Phase IV
Latest Information Update: 06 Jan 2017
At a glance
- Drugs Valsartan (Primary)
- Indications Atrioventricular block; Heart block; Heart failure
- Focus Pharmacodynamics
- 01 Jan 2017 Planned End Date changed from 1 Dec 2017 to 1 Feb 2019.
- 01 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2018.
- 01 Jan 2017 Status changed from not yet recruiting to recruiting.